Gary Robinson, MD
Family Medicine · Lumberton, NCNPI 1457416778
Payments from drug & device makers
Across 111 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$437
- Lilly USA, LLC$196
- AbbVie$136
- Exact Sciences$135
- Sanofi-aventis U.S. LLC$122
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$118
- plus $806 from 19 others
What the payments were for
- Food & beverage$1,950100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $437 |
| Lilly USA, LLC | 12 | $196 |
| AbbVie | 8 | $136 |
| Exact Sciences | 7 | $135 |
| Sanofi-aventis U.S. LLC | 7 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $118 |
| Boehringer Ingelheim | 7 | $113 |
| Novartis | 7 | $112 |
| GSK | 6 | $95 |
| Preventric Diagnostics, Inc. | 1 | $75 |
| Johnson & Johnson | 4 | $60 |
| AstraZeneca | 3 | $50 |
| Amgen | 3 | $39 |
| Boston Scientific | 1 | $37 |
| Medtronic | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $33 |
| Abbott | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
How this compares
$1,950 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 188 | $183,338 |
| JardianceEmpagliflozin | 61 | $80,166 |
| EliquisApixaban | 70 | $60,901 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $54,737 |
| LinzessLinaclotide | 72 | $54,037 |
| TrulicityDulaglutide | 38 | $43,652 |
| FarxigaDapagliflozin Propanediol | 42 | $40,782 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $39,595 |
| TradjentaLinagliptin | 40 | $31,411 |
| XareltoRivaroxaban | 33 | $29,921 |
| MyrbetriqMirabegron | 32 | $28,898 |
| RybelsusSemaglutide | 13 | $12,476 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $10,684 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $10,524 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $437 | $195,814201 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $113 | $122,260123 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $50 | $57,74271 claims |
| AbbVieLinzess | $136 | $54,03772 claims |
| Lilly USA, LLCTrulicity | $196 | $43,65238 claims |
| GSKTrelegy Ellipta | $95 | $39,59551 claims |
| Johnson & JohnsonXarelto | $60 | $29,92133 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $122 | $10,43412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Lumberton
- Muhammad ZafarLumberton$244K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.